IN2014CN04067A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04067A
IN2014CN04067A IN4067CHN2014A IN2014CN04067A IN 2014CN04067 A IN2014CN04067 A IN 2014CN04067A IN 4067CHN2014 A IN4067CHN2014 A IN 4067CHN2014A IN 2014CN04067 A IN2014CN04067 A IN 2014CN04067A
Authority
IN
India
Prior art keywords
cancer
vegf
met
directed
treatment
Prior art date
Application number
Inventor
Dana T Aftab
Frauke Schimmoller
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of IN2014CN04067A publication Critical patent/IN2014CN04067A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

This invention is directed to the treatment of cancer particularly castration resistant prostate cancer and bone metastases with a dual inhibitor of MET and VEGF.
IN4067CHN2014 2011-11-08 2012-11-08 IN2014CN04067A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161557358P 2011-11-08 2011-11-08
PCT/US2012/064116 WO2013070890A1 (en) 2011-11-08 2012-11-08 Dual inhibitor of met and vegf for treating cancer

Publications (1)

Publication Number Publication Date
IN2014CN04067A true IN2014CN04067A (en) 2015-10-23

Family

ID=47179011

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4067CHN2014 IN2014CN04067A (en) 2011-11-08 2012-11-08

Country Status (15)

Country Link
US (1) US20140323522A1 (en)
EP (1) EP2776033A1 (en)
JP (2) JP2014532766A (en)
KR (1) KR20140088610A (en)
CN (1) CN104159585A (en)
AU (2) AU2012335737A1 (en)
BR (1) BR112014011009A2 (en)
CA (1) CA2854336A1 (en)
EA (1) EA201490944A1 (en)
HK (1) HK1202062A1 (en)
IL (1) IL232421A0 (en)
IN (1) IN2014CN04067A (en)
MX (1) MX2014005458A (en)
TW (2) TWI662962B (en)
WO (1) WO2013070890A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA108618C2 (en) 2009-08-07 2015-05-25 APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
JP6158705B2 (en) 2010-09-27 2017-07-05 エクセリクシス， インク． Dual inhibitors of MET and VEGF for the treatment of castration resistant prostate cancer and osteogenic metastases
KR20210010671A (en) 2011-02-10 2021-01-27 엑셀리시스, 인코포레이티드 Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
TWI610918B (en) 2011-05-02 2018-01-11 艾克塞里克斯公司 Method of treating cancer and bone cancer pain
AU2012312364B2 (en) 2011-09-22 2017-11-09 Exelixis, Inc. Method for treating osteoporosis
PT2768796T (en) 2011-10-20 2020-02-21 Exelixis Inc Process for preparing quinoline derivatives
US9861624B2 (en) * 2012-05-02 2018-01-09 Exelixis, Inc. Method of treating cancer
BR112015023109A2 (en) 2013-03-15 2018-05-15 Exelixis Inc METABOLITES OF N- (4 - {[6,7-BIS (METHYLOXY) QUINOLOIN-4-IL] OXY} PHENYL) -N - (4-FLUOROFENYL) CYCLOPROPANE-1, 1-DICARBOXAMIDE
US11564915B2 (en) 2013-04-04 2023-01-31 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
US9149471B2 (en) * 2013-09-30 2015-10-06 National University Corporation Tokyo University Of Agriculture And Technology Therapeutic agent for osteoporosis
MX2016010266A (en) 2014-02-14 2017-02-08 Exelixis Inc Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy] phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use.
CN106255499A (en) 2014-03-17 2016-12-21 埃克塞里艾克西斯公司 The rich administration for Buddhist nun's preparation of card
CN104788372B (en) * 2014-07-25 2018-01-30 上海圣考医药科技有限公司 A kind of deuterated card is rich to replace Buddhist nun's derivative, its preparation method, application and its intermediate
US11124481B2 (en) 2014-07-31 2021-09-21 Exelixis, Inc. Method of preparing fluorine-18 labeled Cabozantinib and its analogs
CN106573042A (en) 2014-08-05 2017-04-19 埃克塞里艾克西斯公司 Drug combinations to treat multiple myeloma
CN105503717A (en) * 2014-09-24 2016-04-20 江苏奥赛康药业股份有限公司 Cabozantinib malate compound and medicine composition therewith
CN109069499A (en) * 2016-04-15 2018-12-21 埃克塞里艾克西斯公司 Use N- (4- (6,7- dimethoxy-quinoline -4- base oxygroup) phenyl)-N '-(4- fluorophenyl) cyclopropane -1,1- diformamide, the method for (2S)-hydroxysuccinic acid salts for treating clear-cell carcinoma
AU2017346104B2 (en) * 2016-10-18 2020-06-11 Beijing Konruns Pharmaceutical Co., Ltd. Quinolinyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition thereof, and use thereof
EA039654B1 (en) 2017-05-26 2022-02-22 Экселиксис, Инк. Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorphenyl)cyclopropane-1,1-dicarboxamide, processes for making and methods of use
JP7321165B2 (en) 2018-01-26 2023-08-04 エグゼリクシス， インコーポレイテッド Compounds for treating kinase dependent disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2537812C (en) 2003-09-26 2013-01-22 Exelixis, Inc. C-met modulators and method of use
WO2008083319A1 (en) 2006-12-29 2008-07-10 Il Yang Pharmaceutical Company, Ltd. Solid state forms of enantiopure ilaprazole
UA108618C2 (en) * 2009-08-07 2015-05-25 APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
JP6158705B2 (en) * 2010-09-27 2017-07-05 エクセリクシス， インク． Dual inhibitors of MET and VEGF for the treatment of castration resistant prostate cancer and osteogenic metastases
US20140057908A1 (en) * 2010-09-27 2014-02-27 Exelixis, Inc. Method of Treating Cancer

Also Published As

Publication number Publication date
CN104159585A (en) 2014-11-19
US20140323522A1 (en) 2014-10-30
CA2854336A1 (en) 2013-05-16
TW201818937A (en) 2018-06-01
JP2018048154A (en) 2018-03-29
EP2776033A1 (en) 2014-09-17
KR20140088610A (en) 2014-07-10
AU2012335737A1 (en) 2014-06-05
MX2014005458A (en) 2015-04-16
TWI662962B (en) 2019-06-21
TW201322981A (en) 2013-06-16
JP2014532766A (en) 2014-12-08
BR112014011009A2 (en) 2017-06-06
IL232421A0 (en) 2014-06-30
EA201490944A1 (en) 2014-10-30
HK1202062A1 (en) 2015-09-18
WO2013070890A1 (en) 2013-05-16
AU2017225103A1 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
IN2014CN04067A (en)
MX2013003594A (en) Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases.
HK1202253A1 (en) Combination treatment of cancer
IL304337A (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
SG10201508495VA (en) Combination treatment of cancer
BR112013024211A2 (en) solid tumor treatment
MX2011011431A (en) Composition for the treatment of prostate cancer.
IL225689A0 (en) Treatment of cancer/inhibition of metastasis
IL228430A0 (en) Treatment of cancer
ZA201300762B (en) Novel combination therapy for the treatment of cancer
IN2014DN00254A (en)
MX2013006526A (en) Dosages of arylsulfonamide derivatives.
GB201017316D0 (en) Treatment of cancer/inhibition of metastasis
GB201121791D0 (en) Combination treatment of cancer
GB201017356D0 (en) Combination treatment of cancer
GB201017354D0 (en) Treatment of cancer
JO3550B1 (en) Composition for the Treatment of Prostate Cancer
GB201121783D0 (en) Treatment of cancer
TH0901005197A (en) Anti-angiogenic therapy for the treatment of breast cancer